← All indications
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
Drugs by status
Approved for this indication (4)
Phase 4 trials (3)
Phase 3 trials (65)
- carboplatin
- autologous monocytes
- escitalopram
- sargramostim
- chloroquine
- transforming growth factor(alpha)-pseudomonas aeruginosa exotoxin
- imatinib
- tofacitinib
- siroquine
- flucytosine
- nivolumab
- asc40
- marizomib
- dendritic cells loaded with glioblastoma
- niraparib
- fluorescein
- sulfur hexafluoride lipid-type a microspheres
- chlorogenic acid
- losartan
- allogeneic hematopoietic stem cells
- plb1001
- rindopepimut
- aminolevulinic acid
- antigen pulsed dendritic cells
- ict-107
- paricalcitol
- semustine
- vocimagene amiretrorepvec
- veliparib
- Fluoroethyl-L-tyrosine
- +35 more
Phase 2 trials (367)
- l19tnf
- methoxyamine
- camrelizumab
- aflibercept
- msc11fcd
- fludeoxyglucose f-18
- capmatinib
- BL-B01D1
- aglatimagene besadenovec
- gefitinib
- tioguanine
- Trotabresib
- ds-1001b
- lopinavir
- tsr-022
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- autologous dendritic cells loaded with autologous tumor lysate
- sl-701
- incagn01876
- epothilone
- carboxyamidotriazole
- atezolizumab
- debio 0123
- talazoparib
- fludarabine
- tg6002
- lapatinib
- d2c7
- abemaciclib
- anlotinib
- +337 more
Phase 1 trials (244)
- 68ga-rm2
- lb-100
- ad-hcmv-flt3l
- autologous dendritic cells pulsed with multiple neoantigen peptides.
- nkg2d car-t cell
- gadopenteate dimeglumine
- trimethoprim
- macitentan
- prt3645
- egfrviii car t cells
- incb024360
- car.b7-h3
- sertraline
- lidocaine
- egfr(v)-edv-dox
- 177lu-rm2
- ly3214996
- imiquimod
- fosphenytoin
- pioglitazone
- incb7839
- 13c-pyruvate
- f 18 dasa-23
- captopril
- her.car cmv-specific ctls
- tadalafil
- raclopride
- allogeneic cd34+ cells
- ts-2021
- rsc-1255
- +214 more
Other trials (26)
- fpprgd2
- gadobenate
- gadobutrol
- bvd-523
- protoporhyrin ix
- zinc
- mab-425
- f-18-psma-1007
- genetically-modified neural stem cells expressing e.coli cytosine deaminase
- pbr
- bafetinib
- hydrocortisone
- allogeneic gamma-delta t cells
- 18f-fluoro-dihydroxyphenylalanine
- etanidazole
- 89zr-j591
- ga 68-edotreotide
- avm0703
- khk2455
- autologous lymphocytes
- beractant
- 125-iodine
- methionine
- nm404
- dcvax-l
- Silibinin
Organizations
Organization Involved with Phase 3 Indications (119)
- Lund University
- University of Paris
- Deutsche Kinderkrebsstiftung
- Chinese Academy of Medical Sciences
- Chang Gung University
- University of California, San Francisco
- Cornell University
- University of Oslo
- Japan Clinical Oncology Group
- Johnpro Biotech, Inc.
- Northwest Biotherapeutics
- University of Bologna
- Tel Aviv University
- NeuroVita Clinic
- Eli Lilly
- University of California, Los Angeles
- ZAO NeuroVita Clinic of Interventional and Restorative Neurology and Therapy
- University of Mannheim
- Duke University
- Kintara Therapeutics, Inc.
- University of Goettingen
- Merck Serono
- Harvard University
- Capital Medical University
- Radiation Therapy Oncology Group
- University of Toulouse
- Centre Leon Berard
- Sichuan University
- McGill University
- ImmunoCellular Therapeutics, Ltd.
- +89 more
Organization Involved with Phase 2 Indications (373)
- Hacettepe University
- Hebrew University
- Angiochem Inc
- Chittaranjan National Cancer Institute
- University of Cincinnati
- Thallion Pharmaceuticals
- Covance
- Cha Medical University
- University of Maryland
- University of Leeds
- Noxxon AG
- Neurocrine Biosciences
- Université catholique de Louvain
- BTG
- CANbridge Life Sciences Ltd.
- Peninsula Health
- Immunomedics
- Region Skane
- Olympion Medical Center
- Medical University Innsbruck
- Myrexis Inc.
- Methodist Healthcare
- University of Massachusetts
- Guangzhou Trinomab Biotech Co., Ltd.
- Guangxi Medical University
- Boneca Corporation
- Geisinger Clinic
- Genexine, Inc.
- Oakland University
- Incheon St.Mary's Hospital
- +343 more
Organization Involved with Phase 1 Indications (96)
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- Sutter Health
- University of Basel
- Philadelphia College of Osteopathic Medicine
- ORION Clinical Services
- NantWorks
- Genzyme
- Providence Health & Services
- Inova Health System
- University of Tuebingen
- University of Stavanger
- BCN Peptides
- Biontech
- Takeda
- Apollomics, Inc.
- Fortress Biotech
- Olivia Newton-John Cancer Research Institute
- Ariad Pharmaceuticals
- Nucleus Network Ltd
- Humanigen
- Stony Brook University
- Solving Kids’ Cancer
- Garnett McKeen Laboratory Inc.
- Cooper Human Systems
- Government of Belgium
- University of Minnesota
- Global Neurosciences Institute
- OX2 Therapeutics
- Phase One Foundation
- Aix-University of Marseille
- +66 more
Organization Involved with Other Experimental Indications (14)